Clinical Trial Update: Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A [Phase 1]

View source ↗

Summary

Phase 1 clinical trial completion evaluating how NovoEight (turoctog alfa) pharmacokinetics relate to BMI in individuals with Haemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NovoEight (turoctocog alfa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED